PTI 801 - Proteostasis Therapeutics

Drug Profile

PTI 801 - Proteostasis Therapeutics

Alternative Names: PTI-801 - Proteostasis

Latest Information Update: 18 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 08 Jan 2018 Proteostasis Therapeutics plans a triple combination proof of concept trial combining PTI 428, PTI 801 and PTI 808 for Cystic fibrosis in first half of 2018
  • 11 Dec 2017 Safety, efficacy, pharmacokinetics and drug-interaction data from a phase I trial in Cystic fibrosis released by Proteostasis Therapeutics
  • 14 Nov 2017 Proteostasis Therapeutics plans a clinical trial for Cystic fibrosis (Combination therapy, in combination with PTI 808) in the fourth quarter of 2017 (Trial profile 700290603)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top